Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Folicrex may help with hair growth and health but lacks clinical evidence.

This article discusses the global interest and market presence of biotin-based supplements like Folexin for preventing alopecia, but it reports no new research findings.

This study evaluated the 308-nm excimer laser as an adjuvant treatment for frontal fibrosing alopecia and found it may stabilize hairline recession and improve erythema and perifollicular hyperkeratosis, with transient erythema as the only reported adverse effect.

This review explores current therapeutic options for frontal fibrosing alopecia, noting the use of finasteride, topical tacrolimus, hydroxychloroquine, and excimer laser in managing the condition, but reports no new clinical results.

This study reviewed 18 postmenopausal women with frontal fibrosing alopecia, noting frontotemporal hairline recession and eyebrow loss, often treated with steroids, triamcinolone, and other medications.

This case report describes successful treatment of folliculitis decalvans in a 41-year-old woman using oral fusidic acid, leading to clinical improvement and no recurrences after six months.

This review discusses frontal fibrosing alopecia and reports no clinical results; the authors note that no therapeutic options tested, including corticosteroids, finasteride, and minoxidil, have shown clear benefits.

This study found that applying Crescina® HFSC lotion for four months effectively increased hair growth and reduced hair loss in males with androgenetic alopecia.

This letter reports on a case of intractable ophiasis-type alopecia areata that was presumably improved by fexofenadine, but no new clinical results are presented.

In this case study, a 35-year-old man with recalcitrant folliculitis decalvans was successfully treated with Erbium-YAG laser, showing rapid improvement without hair loss, though further clinical studies are needed to define its benefits more comprehensively.

Oral dutasteride and topical pimecrolimus can safely and effectively treat Frontal Fibrosing Alopecia, leading to significant hair regrowth.

In this clinical experience, treating frontal fibrosing alopecia with oral finasteride, hydroxychloroquine, tacrolimus, and excimer laser was associated with optimal results in patients with active inflammation.

This study investigated a finasteride and oregano oil-loaded nano-cubosome gel formulation, finding it enhanced drug release and skin permeation and demonstrated synergistic antibacterial effects, suggesting potential for treating alopecia areata.

In this case study, oral folic acid therapy resulted in noticeable improvement and eventual recovery from hair loss and skin issues in a three-week-old Charolais calf.

In this study, the researchers found no superiority of combining 308-nm excimer laser with intralesional corticosteroid over corticosteroid alone for treating frontal fibrosing alopecia, and reported side effects such as erythema and postinflammatory hyperpigmentation in both treatment groups.

This case report describes a patient with frontal fibrosing alopecia experiencing significant hair regrowth and reversal of cutaneous atrophy after treatment with the 5α-reductase inhibitor finasteride.

This study found that early intervention and treatment with intralesional triamcinolone acetonide may stabilize hairline recession in patients with frontal fibrosing alopecia, although further research is needed for definitive treatment guidelines.

This study observed that combining high-potency steroids with pimecrolimus might effectively stabilize hairline recession in frontal fibrosing alopecia patients.

This study reports two cases of alopecia areata that responded to the antihistamine fexofenadine.

This review discusses the potential benefits of folate supplementation to mitigate methotrexate side effects in psoriasis patients and reports no new clinical data, suggesting further randomized controlled trials are needed.

This study found that nanofat injections significantly improved scar characteristics, including collagen deposition, epidermal thickness, and vascularity, due to its anti-inflammatory and immunomodulatory properties.

This study found that eflornithine 15% cream reduced unwanted facial hair growth more effectively than a placebo in women with hirsutism, but hair growth returned to pretreatment levels within 8 weeks of stopping treatment.

This review summarizes the current treatment modalities for frontal fibrosing alopecia and provides a practical guide for clinicians, but reports no new clinical results.

In this study of women with frontal fibrosing alopecia, delgocitinib cream improved the molecular signature of lesions and demonstrated potential as a treatment, showing significant transcriptomic changes and some clinical improvements over 12 weeks compared to a cream vehicle.

This case study documented a 36-year-old woman with postpartum-onset frontal fibrosing alopecia who showed significant improvement in hair regrowth after early combination therapy with dutasteride, tofacitinib, and intralesional triamcinolone acetonide, suggesting potential benefits of multimodal treatment in this typically irreversible condition.

This review highlights available treatments for frontal fibrosing alopecia, noting that 5-alpha reductase inhibitors, intralesional steroids, and hydroxychloroquine currently have the most evidence supporting their use, while other treatments show variable results and require further study.

This study found that a topical lotion containing minoxidil, hydrocortisone butyrate, and 17α-estradiol improved or stabilized frontal fibrosing alopecia in 35 out of 40 women over 36 months.

In this study, 2′‐Fucosyllactose (2′‐FL) administration significantly reduced hair loss and increased hair length and thickness in a testosterone-induced androgenic alopecia mouse model, suggesting potential as a therapeutic agent for AGA.